Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): consultee and commentator comments on the ACD
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Roche Products
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Ovacome
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Target Ovarian Cancer
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Nursing
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Pathologists
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Royal College of Physicians (NCRI Gynaecological Cancer Clinical Studies Group/RCP/RCR/ACP/JCCO)
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Department of Health
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): NHS outer north east London cluster
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Commissioning Support Appraisals Service
Ovarian cancer (metastatic) - bevacizumab (with paclitaxel and carboplatin): Southampton Health Technology Assessments Centre
This page was last updated: 22 March 2013